NTLA
Intellia Therapeutics, Inc.
There isn't enough reported data to score NTLA yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NTLA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NTLA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NTLA PE Valuation
NTLA has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NTLA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NTLA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NTLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.33 | +$0.94 |
| Q2 2026 | -$3.34 | +$1.35 |
| Q1 2026 | -$3.52 | +$1.71 |
| Q4 2025 | -$3.81 | +$1.44 |
| Q3 2025 | -$4.27 | +$1.17 |
| Q2 2025 | -$4.69 | +$0.79 |
| Q1 2025 | -$5.23 | +$0.13 |
| Q4 2024 | -$5.25 | +$0.16 |
NTLA is still losing money, but less than at its worst: $3.33 per share over the past year, against $6.16 at its worst in late 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NTLA on earnings quality, reporting a profit while its opponent remains loss making.
NTLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.2M | -48% |
| Q2 2026 | $7.7M | -46% |
| Q1 2026 | $15M | -9.5% |
| Q4 2025 | $23M | +79% |
| Q3 2025 | $13.8M | +51% |
| Q2 2025 | $14.2M | +105% |
| Q1 2025 | $16.6M | -43% |
| Q3 2024 | $9.1M | -24% |
NTLA's revenue has slid since its 2024 peak: $7M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1708% | -899 points |
| Q2 2026 | -1472% | -700 points |
| Q1 2026 | -668% | +59 points |
| Q4 2025 | -429% | +631 points |
| Q3 2025 | -809% | +780 points |
| Q2 2025 | -772% | +1226 points |
| Q1 2025 | -727% | -333 points |
| Q4 2024 | -1060% | N/A |
NTLA's operating margin was −1708% last quarter, down 899 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over NTLA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NTLA on profitability, with a higher operating margin.
NTLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$86.3M | -$9.4M |
| Q2 2026 | -$84.9M | +$14.9M |
| Q1 2026 | -$117.4M | +$32.2M |
| Q4 2025 | -$69.4M | +$16.8M |
| Q3 2025 | -$76.9M | +$9.2M |
| Q2 2025 | -$99.9M | -$40.7M |
| Q1 2025 | -$149.7M | -$26.5M |
| Q4 2024 | -$86.2M | +$8.4M |
NTLA has burned cash in almost every quarter: −$358M over the past year, against −$413M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over NTLA on cash generation, producing positive trailing cash flow while its opponent burns cash.
NTLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5% | +6.7M shares |
| 1 year | +27% | +30M shares |
| 3 years | +58% | +51.5M shares |
| 5 years | +106% | +72M shares |
| Available history | +184% | +90.8M shares |
NTLA has 140M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NTLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NTLA Net Leverage
NTLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NTLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 30.2 | Neutral |
NTLA's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NTLA PE vs Healthcare Sector
NTLA has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NTLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 10% below |
| 20 week MA | $12.2 | 14% below |
| 50 week MA | $12.5 | 16% below |
| 100 week MA | $11.9 | 11% below |
| 200 week MA | $20.8 | 49% below |
NTLA is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NTLA on trend strength, trading above more of its moving averages.
NTLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.4 | $62.1 | +304% |
| 2021 | $62.1 | $126.8 | +104% |
| 2022 | $126.8 | $35.0 | -72% |
| 2023 | $35.0 | $30.5 | -13% |
| 2024 | $30.5 | $12.0 | -61% |
| 2025 | $12.0 | $9.44 | -21% |
| 2026 YTD | $9.44 | $10.6 | +12% |
NTLA has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.